Technology News Update : Lupin Launches Penicillamine Tablets USP

Insight Online News

Mumbai, Mar 3 : Pharma major Lupin on Wednesday announced the launch of Penicillamine Tablets USP, 250 mg, having received an approval from the United States Food and Drug Administration (USFDA) earlier.


Penicillamine Tablets USP, 250 mg, are the generic equivalent of Depen Tablets, 250 mg, of Mylan Specialty, L P, and indicated in the treatment of Wilson’s disease, Cystinuria, and in patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy.

Penicillamine Tablets USP, 250 mg had estimated annual sales of USD 5 million in the US (IQVIA MAT December 2020).

UNI

Leave a Reply

Your email address will not be published. Required fields are marked *